Ivabradine: A Review of Labeled and Off-Label Uses

Carrie S. Oliphant, Ryan E. Owens, Oluwaseyi B. Bolorunduro, Sunil Jha

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Ivabradine is a unique medication recently approved in the USA for the treatment of select heart failure patients. It was first approved for use in several countries around the world over a decade ago as an anti-anginal agent, with subsequent approval for use in heart failure patients. Since ivabradine has selective activity blocking the If currents in the sinus node, it can reduce heart rate without appreciable effects on blood pressure. Given this heart-rate-specific effect, it has been investigated in many off-label indications as an alternative to traditional heart-rate-reducing medications such as beta blockers and calcium channel blockers. We conducted searches of PubMed and Google Scholar for ivabradine, heart failure, HFrEF, HFpEF, angina, coronary artery disease, inappropriate sinus tachycardia, postural orthostatic hypotension, coronary computed tomography angiography and atrial fibrillation. We reviewed and included studies, case reports, and case series published between 1980 and June 2016 if they provided information relevant to the practicing clinician. In many cases, larger clinical trials are needed to solidify the benefit of ivabradine, although studies indicate benefit in most therapeutic areas explored to date. The purpose of this paper is to review the current labeled and off-label uses of ivabradine, with a focus on clinical trial data.

Original languageEnglish (US)
Pages (from-to)337-347
Number of pages11
JournalAmerican Journal of Cardiovascular Drugs
Volume16
Issue number5
DOIs
StatePublished - Oct 1 2016

Fingerprint

ivabradine
Off-Label Use
Orthostatic Hypotension
Heart Failure
Heart Rate
Clinical Trials
Sinus Tachycardia
Sinoatrial Node
Calcium Channel Blockers
PubMed
Atrial Fibrillation
Coronary Artery Disease
Blood Pressure
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Ivabradine : A Review of Labeled and Off-Label Uses. / Oliphant, Carrie S.; Owens, Ryan E.; Bolorunduro, Oluwaseyi B.; Jha, Sunil.

In: American Journal of Cardiovascular Drugs, Vol. 16, No. 5, 01.10.2016, p. 337-347.

Research output: Contribution to journalReview article

Oliphant, Carrie S. ; Owens, Ryan E. ; Bolorunduro, Oluwaseyi B. ; Jha, Sunil. / Ivabradine : A Review of Labeled and Off-Label Uses. In: American Journal of Cardiovascular Drugs. 2016 ; Vol. 16, No. 5. pp. 337-347.
@article{e8702d441bf14085945283b1c405f856,
title = "Ivabradine: A Review of Labeled and Off-Label Uses",
abstract = "Ivabradine is a unique medication recently approved in the USA for the treatment of select heart failure patients. It was first approved for use in several countries around the world over a decade ago as an anti-anginal agent, with subsequent approval for use in heart failure patients. Since ivabradine has selective activity blocking the If currents in the sinus node, it can reduce heart rate without appreciable effects on blood pressure. Given this heart-rate-specific effect, it has been investigated in many off-label indications as an alternative to traditional heart-rate-reducing medications such as beta blockers and calcium channel blockers. We conducted searches of PubMed and Google Scholar for ivabradine, heart failure, HFrEF, HFpEF, angina, coronary artery disease, inappropriate sinus tachycardia, postural orthostatic hypotension, coronary computed tomography angiography and atrial fibrillation. We reviewed and included studies, case reports, and case series published between 1980 and June 2016 if they provided information relevant to the practicing clinician. In many cases, larger clinical trials are needed to solidify the benefit of ivabradine, although studies indicate benefit in most therapeutic areas explored to date. The purpose of this paper is to review the current labeled and off-label uses of ivabradine, with a focus on clinical trial data.",
author = "Oliphant, {Carrie S.} and Owens, {Ryan E.} and Bolorunduro, {Oluwaseyi B.} and Sunil Jha",
year = "2016",
month = "10",
day = "1",
doi = "10.1007/s40256-016-0178-z",
language = "English (US)",
volume = "16",
pages = "337--347",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Ivabradine

T2 - A Review of Labeled and Off-Label Uses

AU - Oliphant, Carrie S.

AU - Owens, Ryan E.

AU - Bolorunduro, Oluwaseyi B.

AU - Jha, Sunil

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Ivabradine is a unique medication recently approved in the USA for the treatment of select heart failure patients. It was first approved for use in several countries around the world over a decade ago as an anti-anginal agent, with subsequent approval for use in heart failure patients. Since ivabradine has selective activity blocking the If currents in the sinus node, it can reduce heart rate without appreciable effects on blood pressure. Given this heart-rate-specific effect, it has been investigated in many off-label indications as an alternative to traditional heart-rate-reducing medications such as beta blockers and calcium channel blockers. We conducted searches of PubMed and Google Scholar for ivabradine, heart failure, HFrEF, HFpEF, angina, coronary artery disease, inappropriate sinus tachycardia, postural orthostatic hypotension, coronary computed tomography angiography and atrial fibrillation. We reviewed and included studies, case reports, and case series published between 1980 and June 2016 if they provided information relevant to the practicing clinician. In many cases, larger clinical trials are needed to solidify the benefit of ivabradine, although studies indicate benefit in most therapeutic areas explored to date. The purpose of this paper is to review the current labeled and off-label uses of ivabradine, with a focus on clinical trial data.

AB - Ivabradine is a unique medication recently approved in the USA for the treatment of select heart failure patients. It was first approved for use in several countries around the world over a decade ago as an anti-anginal agent, with subsequent approval for use in heart failure patients. Since ivabradine has selective activity blocking the If currents in the sinus node, it can reduce heart rate without appreciable effects on blood pressure. Given this heart-rate-specific effect, it has been investigated in many off-label indications as an alternative to traditional heart-rate-reducing medications such as beta blockers and calcium channel blockers. We conducted searches of PubMed and Google Scholar for ivabradine, heart failure, HFrEF, HFpEF, angina, coronary artery disease, inappropriate sinus tachycardia, postural orthostatic hypotension, coronary computed tomography angiography and atrial fibrillation. We reviewed and included studies, case reports, and case series published between 1980 and June 2016 if they provided information relevant to the practicing clinician. In many cases, larger clinical trials are needed to solidify the benefit of ivabradine, although studies indicate benefit in most therapeutic areas explored to date. The purpose of this paper is to review the current labeled and off-label uses of ivabradine, with a focus on clinical trial data.

UR - http://www.scopus.com/inward/record.url?scp=84978161520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978161520&partnerID=8YFLogxK

U2 - 10.1007/s40256-016-0178-z

DO - 10.1007/s40256-016-0178-z

M3 - Review article

C2 - 27405864

AN - SCOPUS:84978161520

VL - 16

SP - 337

EP - 347

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 5

ER -